Skip to main content
. 2017 Jul 21;2(6):1132–1140. doi: 10.1016/j.ekir.2017.07.004

Figure 5.

Figure 5

Time to discontinuation due to aquaretic and non-aquaretic adverse events. Box plot of median and interquartile range of time to discontinuation in the aquaretic-discontinued (AD) and non–aquaretic-discontinued (NAD) groups. Data points above and below the 75th and 25th quartiles are depicted in black circles. The overall ranges were 2 to 877 days in the AD group and 8 to 1050 days in the NAD group. Discont., discontinued; max, maximum; min, minimum; TEMPO 3:4, Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes.